A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
A phase 3 trial of Camizestrant, Tamoxifen and Exemestane in advanced solid tumours, run by AstraZeneca, now recruiting.
Overview
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy is a phase 3 interventional study registered as NCT05774951 by AstraZeneca, with 4300 participants planned, started 2023-03-31 and due to reach its primary completion in 2027-04-20. Interventions recorded: Camizestrant, Tamoxifen, Anastrozole, Letrozole and Exemestane.
Similar pages
not linked directly; found by shared links- TrialOvarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Shares Camizestrant, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
Shares Camizestrant, AstraZeneca and the tag pipeline.
- TrialA Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Shares Camizestrant, AstraZeneca and the tag pipeline.
- TrialSirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
Shares Exemestane, Metastatic cancer (cancer that has spread) and the tag pipeline.